NEWS

Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate

March 31, 2022

AGC Biologics is producing vaccine materials for early-stage product trials at its Heidelberg facilities

AGC Biologics Supports BioNTech Omicron-based Vaccine Candidate with pDNA Starting Material

February 08, 2022

AGC Biologics announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility

I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project

AGC Biologics today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment being developed is approaching late-phase clinical trials and AGC Biologics will manufacture the materials at its site in Seattle, while also supporting the launch readiness of I-MAB’s product.

AGC Biologics Receives Transatlantic Award for Investments in Milan Biopharmaceutical Industry

December 07, 2021

AGC Biologics today announced it won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy (AmCham). The company was named the 2021 winner for its investments in the Italian biopharmaceutical industry, which includes expansion at its Center of Excellence in Milan to make it a global hub for cell and gene therapy innovation, development and manufacturing.

4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab

December 01, 2021

AGC Biologics to produce Procizumab for early and late clinical Phases at the company’s Chiba and Copenhagen facilities

AGC Biologics Expands pDNA and mRNA Manufacturing Capacity

September 13, 2021

AGC Biologics today announced expansion plans for the company’s Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.

AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site

August 20, 2021

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announces the groundbreaking of its new facility at its Copenhagen, Denmark site. This multipurpose facility will allow AGC Biologics to increase its capacity and space to accommodate new and existing clients’ needs.

Norgine B.V. completes important regulatory milestone for ANGUSTA® (misoprostol) in Europe for oral induction of labour

August 17, 2021

B.V. (Norgine) today announced the successful completion of the Repeat Use Procedure (RUP) for ANGUSTA® in a number of European countries including Austria, Belgium, Cyprus, Germany, Greece, Spain, Ireland, Italy, Luxemburg, Malta, Netherlands, Portugal and the UK.

Bactolife raises EUR 7 million in Seed financing

April 19, 2021

Novo Seeds, the early stage investment and company creation team of Novo Holdings, today announced that it is leading a EUR 7 million seed investment into Bactolife™, a Danish start-up developing novel biological solutions to reduce the risk of gastrointestinal infections in animals and humans alongside existing private investors.

AGC Biologics A/S and Calypso Biotech BV Announce Agreement for Process Development and cGMP Manufacture of CALY-002

February 19, 2019

AGC Biologics have announced today that they have entered into an agreement for the process development and cGMP manufacture of CALY-002, a humanized monoclonal antibody inhibiting Interleukin-15 (IL-15).

AGC Biologics Adds Mammalian Production Capacity in Japan

September 21, 2018

AGC Biologics, announced it will establish a new state of the art process development and manufacturing facility at its CDMO facility in Chiba, Japan.

AGC Biologics Expands Capacity at Copenhagen, Denmark Facility

August 22, 2018

AGC Biologics announced that as part of its global expansion strategy, the company is increasing manufacturing capacity at its Copenhagen, Denmark facility.

AGC Biologics Inaugurates New Global Headquarters Facility in Bothell, WA

July 25, 2018

AGC Biologics celebrated the opening of the company’s new Global Headquarters facility in Bothell, Washington

AGC Biologics Cleared for Commercial Manufacture of Portola's FDA-Approved Andexxa®

May 24, 2018

AGC Biologics announced today that it will supply bulk drug substance for the launch of Portola Pharmaceuticals' Andexxa®, the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

AGC Biologics enters into Commercial Supply Agreement with MacroGenics

May 10, 2018

AGC Biologics has entered into a commercial supply agreement with MacroGenics for the manufacture of margetuximab, a clinical-stage, novel immune-optimized monoclonal antibody.

AGC Biologics enters into Commercial Manufacturing Agreement with Horizon Pharma plc

May 03, 2018

AGC Biologics t has entered into an agreement with Horizon Pharma plc for commercial supply of teprotumumab, a monoclonal antibody biologic for the treatment of moderate-to-severe active thyroid eye disease (TED).

Polyvac® Peanut CMO appointed

April 23, 2018

Allergy Therapeutics plc (AIM:AGY), announces it has signed a contract with AGC Biologics to scale up the manufacturing of its Polyvac® Peanut product for use in clinical studies.

AGC Biologics Increases Footprint in Bothell, WA

March 29, 2018

AGC Biologics announced today the addition of a new building complex that will house the company’s global headquarters in Bothell, Washington.

AGC Biologics Expands Capacity at Berkeley, California Facility

March 06, 2018

AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that their Berkeley, California facility…

AGC Biologics to Hold Technical Seminar in Taiwan

January 22, 2018

AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will hold a…

AGC Bioscience, Biomeva, and CMC Biologics to provide services under the brand AGC Biologics

January 08, 2018

AGC Biologics, a convergence of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics, announced today that effective January…

Angusta® is now approved in 16 EU countries

December 18, 2017

Azanta, a Danish specialty pharmaceutical company dedicated to women's health, is granted Marketing Authorisation for Angusta® in an additional 11 European countries…

CMC Biologics Announces Development and Manufacturing Agreement with Harpoon Therapeutics

December 12, 2017

CMC ICOS Biologics, Inc. ("CMC Biologics"), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Harpoon Therapeutics, an…

CMC Biologics and Aptevo Therapeutics Enter into Commercial Manufacturing Agreement for IXINITY®

August 22, 2017

CMC ICOS Biologics, Inc., a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic…

CMC Biologics Enters into Development and Manufacturing Agreement with Trellis BioScience

July 22, 2017

Development of Trellis' monoclonal antibody (mAb) using CMC Biologics' proprietary CHEF1® Expression Platform and Multi-column Continuous Chromatography (MCC) Technology CMC…

Altor BioScience and CMC Biologics Announce Agreement for Manufacture and Validation of Altor’s IL-15 Superagonist Molecule, ALT-803, for use in Phase 3 Clinical Trials